Xpention Genetics, Inc. Announces Plans for Reverse Stock Split and Name Change as Prelude to New Investment
Published: Aug 13, 2008
CONIFER, CO--(Marketwire - August 12, 2008) - Xpention Genetics, Inc. (OTCBB: XPNG) today announced that a majority of its shareholders approved a proposal to authorize the Board, in its discretion, to effect a reverse split of Xpention's issued and outstanding common stock at a ratio ranging from one-for-ten to one-for-twenty without further action by shareholders and to change the name of the company to Cancer Detection Corporation. As of the end of business on July 24, 2008, there were approximately 96.5 million shares of Xpention's common stock outstanding. The reverse split will not change the number of shares of Xpention's preferred stock authorized, which will remain at 10 million.